The Serotonin 1A (5-HT
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
accepted:
15
05
2023
medline:
28
7
2023
pubmed:
30
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Clinical depression is a common, debilitating and heterogenous disorder. Existing treatments for depression are inadequate for a significant minority of patients and new approaches are urgently needed. A wealth of evidence implicates the serotonin 1A (5-HT
Identifiants
pubmed: 37386328
doi: 10.1007/s40263-023-01014-7
pii: 10.1007/s40263-023-01014-7
doi:
Substances chimiques
Serotonin
333DO1RDJY
Receptor, Serotonin, 5-HT1A
112692-38-3
Antidepressive Agents
0
Selective Serotonin Reuptake Inhibitors
0
Serotonin 5-HT1 Receptor Agonists
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-585Subventions
Organisme : Wellcome Trust
ID : 102176/B/13/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979;16(3):687–99.
pubmed: 530254
Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci. 1988;11(11):496–500. https://doi.org/10.1016/0166-2236(88)90011-2 .
doi: 10.1016/0166-2236(88)90011-2
pubmed: 2469177
Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009;88(1):17–31. https://doi.org/10.1016/j.pneurobio.2009.01.009 .
doi: 10.1016/j.pneurobio.2009.01.009
pubmed: 19428959
pmcid: 2736801
Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252–65.
pubmed: 15309042
pmcid: 446220
Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27(9):703–16. https://doi.org/10.1007/s40263-013-0071-0 .
doi: 10.1007/s40263-013-0071-0
pubmed: 23757185
Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S, et al. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J Comp Neurol. 1996;365(2):289–305. https://doi.org/10.1002/(SICI)1096-9861(19960205)365:2%3c289::AID-CNE7%3e3.0.CO;2-1 .
doi: 10.1002/(SICI)1096-9861(19960205)365:2<289::AID-CNE7>3.0.CO;2-1
pubmed: 8822171
Verge D, Daval G, Patey A, Gozlan H, el Mestikawy S, Hamon M. Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT1A subtype. Eur J Pharmacol. 1985;113(3):463–4. https://doi.org/10.1016/0014-2999(85)90099-8 .
doi: 10.1016/0014-2999(85)90099-8
pubmed: 2931289
Sharp T, Boothman L, Raley J, Queree P. Important messages in the “post”: recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci. 2007;28(12):629–36. https://doi.org/10.1016/j.tips.2007.10.009 .
doi: 10.1016/j.tips.2007.10.009
pubmed: 17996955
Halasy K, Miettinen R, Szabat E, Freund TF. GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur J Neurosci. 1992;4(2):144–53. https://doi.org/10.1111/j.1460-9568.1992.tb00861.x .
doi: 10.1111/j.1460-9568.1992.tb00861.x
pubmed: 12106377
Ogren SO, Eriksson TM, Elvander-Tottie E, D’Addario C, Ekstrom JC, Svenningsson P, et al. The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res. 2008;195(1):54–77. https://doi.org/10.1016/j.bbr.2008.02.023 .
doi: 10.1016/j.bbr.2008.02.023
pubmed: 18394726
Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008;195(1):98–102. https://doi.org/10.1016/j.bbr.2008.05.016 .
doi: 10.1016/j.bbr.2008.05.016
pubmed: 18707769
Sprouse JS, Aghajanian GK. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 1988;27(7):707–15. https://doi.org/10.1016/0028-3908(88)90079-2 .
doi: 10.1016/0028-3908(88)90079-2
pubmed: 2901680
Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1(1):3–9. https://doi.org/10.1002/syn.890010103 .
doi: 10.1002/syn.890010103
pubmed: 3505364
Fukumoto K, Iijima M, Funakoshi T, Chaki S. Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol. 2018;21(4):371–81. https://doi.org/10.1093/ijnp/pyx116 .
doi: 10.1093/ijnp/pyx116
pubmed: 29309585
Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol. 1999;127(8):1751–64. https://doi.org/10.1038/sj.bjp.0702723 .
doi: 10.1038/sj.bjp.0702723
pubmed: 10482904
pmcid: 1566169
Masson J, Emerit MB, Hamon M, Darmon M. Serotonergic signaling: multiple effectors and pleiotropic effects. Wiley Interdiscip Rev Membr Transp Signal. 2012;1(6):685–713. https://doi.org/10.1002/wmts.50 .
doi: 10.1002/wmts.50
Luscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA. G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997;19(3):687–95. https://doi.org/10.1016/s0896-6273(00)80381-5 .
doi: 10.1016/s0896-6273(00)80381-5
pubmed: 9331358
Sun QQ, Dale N. G-proteins are involved in 5-HT receptor-mediated modulation of N- and P/Q- but not T-type Ca2+ channels. J Neurosci. 1999;19(3):890–9. https://doi.org/10.1523/JNEUROSCI.19-03-00890.1999 .
doi: 10.1523/JNEUROSCI.19-03-00890.1999
pubmed: 9920652
pmcid: 6782131
Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. 2001;92(2–3):179–212. https://doi.org/10.1016/s0163-7258(01)00169-3 .
doi: 10.1016/s0163-7258(01)00169-3
pubmed: 11916537
Albert PR, Vahid-Ansari F. The 5-HT1A receptor: signaling to behavior. Biochimie. 2019;161:34–45. https://doi.org/10.1016/j.biochi.2018.10.015 .
doi: 10.1016/j.biochi.2018.10.015
pubmed: 31079617
Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7(4):387–90. https://doi.org/10.1017/S1461145704004535 .
doi: 10.1017/S1461145704004535
pubmed: 15315719
Wang JQ, Mao L. The ERK pathway: molecular mechanisms and treatment of depression. Mol Neurobiol. 2019;56(9):6197–205. https://doi.org/10.1007/s12035-019-1524-3 .
doi: 10.1007/s12035-019-1524-3
pubmed: 30737641
pmcid: 6684449
Prasad S, Ponimaskin E, Zeug A. Serotonin receptor oligomerization regulates cAMP-based signaling. J Cell Sci. 2019. https://doi.org/10.1242/jcs.230334 .
doi: 10.1242/jcs.230334
pubmed: 31371490
pmcid: 6602303
Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology. 2020;177:108155. https://doi.org/10.1016/j.neuropharm.2020.108155 .
doi: 10.1016/j.neuropharm.2020.108155
pubmed: 32522572
Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, Lanfumey L. Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol Pharmacol. 2006;70(3):1013–21. https://doi.org/10.1124/mol.106.022756 .
doi: 10.1124/mol.106.022756
pubmed: 16772521
Kushwaha N, Albert PR. Coupling of 5-HT1A autoreceptors to inhibition of mitogen-activated protein kinase activation via G beta gamma subunit signaling. Eur J Neurosci. 2005;21(3):721–32. https://doi.org/10.1111/j.1460-9568.2005.03904.x .
doi: 10.1111/j.1460-9568.2005.03904.x
pubmed: 15733090
Adayev T, El-Sherif Y, Barua M, Penington NJ, Banerjee P. Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem. 1999;72(4):1489–96. https://doi.org/10.1046/j.1471-4159.1999.721489.x .
doi: 10.1046/j.1471-4159.1999.721489.x
pubmed: 10098853
Menkes DB. Putting serotonin in its place-again. BMJ. 2022;379:o2357. https://doi.org/10.1136/bmj.o2357 .
doi: 10.1136/bmj.o2357
pubmed: 36198406
Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01661-0 .
doi: 10.1038/s41380-022-01661-0
pubmed: 35854107
Jauhar S, Cowen PJ, Browning M. Fifty years on: serotonin and depression. J Psychopharmacol. 2023. https://doi.org/10.1177/02698811231161813 .
doi: 10.1177/02698811231161813
pubmed: 36938996
pmcid: 10101177
Dean J, Keshavan M. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101–11. https://doi.org/10.1016/j.ajp.2017.01.025 .
doi: 10.1016/j.ajp.2017.01.025
pubmed: 28558878
Deakin J. The role of serotonin in depression and anxiety. Eur Psychiatry. 1998;13(Suppl 2):57s–63s. https://doi.org/10.1016/S0924-9338(98)80015-1 .
doi: 10.1016/S0924-9338(98)80015-1
pubmed: 19698674
Kranz GS, Kasper S, Lanzenberger R. Reward and the serotonergic system. Neuroscience. 2010;166(4):1023–35. https://doi.org/10.1016/j.neuroscience.2010.01.036 .
doi: 10.1016/j.neuroscience.2010.01.036
pubmed: 20109531
Merens W, Willem Van der Does AJ, Spinhoven P. The effects of serotonin manipulations on emotional information processing and mood. J Affect Disord. 2007;103(1–3):43–62. https://doi.org/10.1016/j.jad.2007.01.032 .
doi: 10.1016/j.jad.2007.01.032
pubmed: 17363069
Kaufman J, DeLorenzo C, Choudhury S, Parsey RV. The 5-HT1A receptor in major depressive disorder. Eur Neuropsychopharmacol. 2016;26(3):397–410. https://doi.org/10.1016/j.euroneuro.2015.12.039 .
doi: 10.1016/j.euroneuro.2015.12.039
pubmed: 26851834
pmcid: 5192019
Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001;25(6):892–903. https://doi.org/10.1016/S0893-133X(01)00310-4 .
doi: 10.1016/S0893-133X(01)00310-4
pubmed: 11750182
Boldrini M, Underwood MD, Mann JJ, Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res. 2008;42(6):433–42. https://doi.org/10.1016/j.jpsychires.2007.05.004 .
doi: 10.1016/j.jpsychires.2007.05.004
pubmed: 17574270
Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci. 1998;18(18):7394–401. https://doi.org/10.1523/JNEUROSCI.18-18-07394.1998 .
doi: 10.1523/JNEUROSCI.18-18-07394.1998
pubmed: 9736659
pmcid: 6793229
Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry. 2004;55(3):225–33. https://doi.org/10.1016/j.biopsych.2003.09.017 .
doi: 10.1016/j.biopsych.2003.09.017
pubmed: 14744462
Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):319. https://doi.org/10.1186/s12888-016-1025-0 .
doi: 10.1186/s12888-016-1025-0
pubmed: 27623971
pmcid: 5022168
Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34(7):865–77. https://doi.org/10.1016/j.nucmedbio.2007.06.008 .
doi: 10.1016/j.nucmedbio.2007.06.008
pubmed: 17921037
pmcid: 2702715
Parsey RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry. 2010;68(2):170–8. https://doi.org/10.1016/j.biopsych.2010.03.023 .
doi: 10.1016/j.biopsych.2010.03.023
pubmed: 20497898
pmcid: 2900398
Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59(2):106–13. https://doi.org/10.1016/j.biopsych.2005.06.016 .
doi: 10.1016/j.biopsych.2005.06.016
pubmed: 16154547
Shrestha S, Hirvonen J, Hines CS, Henter ID, Svenningsson P, Pike VW, et al. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage. 2012;59(4):3243–51. https://doi.org/10.1016/j.neuroimage.2011.11.029 .
doi: 10.1016/j.neuroimage.2011.11.029
pubmed: 22155042
Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry. 2004;9(4):386–92. https://doi.org/10.1038/sj.mp.4001401 .
doi: 10.1038/sj.mp.4001401
pubmed: 15042104
Kishi T, Meltzer HY, Matsuda Y, Iwata N. Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis. Psychol Med. 2014;44(11):2255–69. https://doi.org/10.1017/S0033291713002857 .
doi: 10.1017/S0033291713002857
pubmed: 24262766
Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111–8. https://doi.org/10.1016/j.brainres.2012.04.032 .
doi: 10.1016/j.brainres.2012.04.032
pubmed: 22608068
Ansseau M, Pitchot W, Moreno AG, Wauthy J, Papart P. Pilot-study of flesinoxan, a 5-ht1a agonist, in major depression - effects on sleep rem latency and body-temperature. Hum Psychopharmacol Clin Exp. 1993;8(4):279–83. https://doi.org/10.1002/hup.470080407 .
doi: 10.1002/hup.470080407
Cowen PJ. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol. 1993;16(Suppl 3):S6-18.
pubmed: 8131155
Pitchot W, Wauthy J, Hansenne M, Pinto E, Fuchs S, Reggers J, et al. Hormonal and temperature responses to the 5-HT1A receptor agonist flesinoxan in normal volunteers. Psychopharmacology. 2002;164(1):27–32. https://doi.org/10.1007/s00213-002-1177-0 .
doi: 10.1007/s00213-002-1177-0
pubmed: 12373416
Voronova IP. 5-HT Receptors and temperature homeostasis. Biomolecules. 2021;11(12):1914. https://doi.org/10.3390/biom11121914 .
doi: 10.3390/biom11121914
pubmed: 34944557
pmcid: 8699715
Anderson IM, Ware CJ, da Roza Davis JM, Cowen PJ. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry. 1992;160:372–8. https://doi.org/10.1192/bjp.160.3.372 .
doi: 10.1192/bjp.160.3.372
pubmed: 1562864
Pan L, Gilbert F. Activation of 5-HT1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology. 1992;56(6):797–802. https://doi.org/10.1159/000126332 .
doi: 10.1159/000126332
pubmed: 1369587
Goodwin GM, De Souza RJ, Green AR. The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology. 1985;24(12):1187–94. https://doi.org/10.1016/0028-3908(85)90153-4 .
doi: 10.1016/0028-3908(85)90153-4
pubmed: 2869435
Hutson PH, Donohoe TP, Curzon G. Hypothermia induced by the putative 5-HT1A agonists LY165163 and 8-OH-DPAT is not prevented by 5-HT depletion. Eur J Pharmacol. 1987;143(2):221–8. https://doi.org/10.1016/0014-2999(87)90536-x .
doi: 10.1016/0014-2999(87)90536-x
pubmed: 2961583
Hillegaart V. Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on core temperature in the rat. Psychopharmacology. 1991;103(3):291–6. https://doi.org/10.1007/BF02244281 .
doi: 10.1007/BF02244281
pubmed: 1829235
McAllister-Williams RH, Massey AE, Fairchild G. Repeated cortisol administration attenuates the EEG response to buspirone in healthy volunteers: evidence for desensitization of the 5-HT1A autoreceptor. J Psychopharmacol. 2007;21(8):826–32. https://doi.org/10.1177/0269881107078292 .
doi: 10.1177/0269881107078292
pubmed: 17715208
Young AH, Sharpley AL, Campling GM, Hockney RA, Cowen PJ. Effects of hydrocortisone on brain 5-HT function and sleep. J Affect Disord. 1994;32(2):139–46. https://doi.org/10.1016/0165-0327(94)90072-8 .
doi: 10.1016/0165-0327(94)90072-8
pubmed: 7829766
Lesch KP. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(6):723–33. https://doi.org/10.1016/0278-5846(91)90001-h .
doi: 10.1016/0278-5846(91)90001-h
pubmed: 1763190
Meltzer HY, Maes M. Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biol Psychiatry. 1995;38(7):450–7. https://doi.org/10.1016/0006-3223(94)00370-i .
doi: 10.1016/0006-3223(94)00370-i
pubmed: 8672605
Shapira B, Newman ME, Gelfin Y, Lerer B. Blunted temperature and cortisol responses to ipsapirone in major depression: lack of enhancement by electroconvulsive therapy. Psychoneuroendocrinology. 2000;25(5):421–38. https://doi.org/10.1016/s0306-4530(99)00067-0 .
doi: 10.1016/s0306-4530(99)00067-0
pubmed: 10818278
Riedel WJ, Klaassen T, Griez E, Honig A, Menheere PP, van Praag HM. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology. 2002;26(3):358–67. https://doi.org/10.1016/S0893-133X(01)00361-X .
doi: 10.1016/S0893-133X(01)00361-X
pubmed: 11850150
Navines R, Martin-Santos R, Gomez-Gil E, Martinez de Osaba MJ, Imaz ML, Gasto C. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology. 2007;32(4):411–6. https://doi.org/10.1016/j.psyneuen.2007.01.006 .
doi: 10.1016/j.psyneuen.2007.01.006
pubmed: 17337123
Gray NA, Milak MS, DeLorenzo C, Ogden RT, Huang YY, Mann JJ, et al. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry. 2013;74(1):26–31. https://doi.org/10.1016/j.biopsych.2012.11.012 .
doi: 10.1016/j.biopsych.2012.11.012
pubmed: 23374637
pmcid: 3690146
Lemonde S, Turecki G, Bakish D, Du LS, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23(25):8788–99.
doi: 10.1523/JNEUROSCI.23-25-08788.2003
pubmed: 14507979
pmcid: 6740417
Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist. 2004;10(6):575–93. https://doi.org/10.1177/1073858404267382 .
doi: 10.1177/1073858404267382
pubmed: 15534042
Hesselgrave N, Parsey RV. Imaging the serotonin 1A receptor using [11C]WAY100635 in healthy controls and major depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120004. https://doi.org/10.1098/rstb.2012.0004 .
doi: 10.1098/rstb.2012.0004
pubmed: 23440462
pmcid: 3638381
Lothe A, Boni C, Costes N, Bouvard S, Gorwood P, Lavenne F, et al. 5-HT1A gene promoter polymorphism and [18F]MPPF binding potential in healthy subjects: a PET study. Behav Brain Funct. 2010;6:37. https://doi.org/10.1186/1744-9081-6-37 .
doi: 10.1186/1744-9081-6-37
pubmed: 20609217
pmcid: 2909987
David SP, Murthy NV, Rabiner EA, Munafo MR, Johnstone EC, Jacob R, et al. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci. 2005;25(10):2586–90. https://doi.org/10.1523/JNEUROSCI.3769-04.2005 .
doi: 10.1523/JNEUROSCI.3769-04.2005
pubmed: 15758168
pmcid: 1942077
Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004;7(4):501–6. https://doi.org/10.1017/S1461145704004699 .
doi: 10.1017/S1461145704004699
pubmed: 15447813
Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7(4):453–60. https://doi.org/10.1017/S1461145704004687 .
doi: 10.1017/S1461145704004687
pubmed: 15458611
Seletti B, Benkelfat C, Blier P, Annable L, Gilbert F, Demontigny C. Serotonin(1a) receptor activation by flesinoxan in humans – body-temperature and neuroendocrine responses. Neuropsychopharmacology. 1995;13(2):93–104.
doi: 10.1016/0893-133X(95)00025-9
pubmed: 8597527
Newman-Tancredi A, Depoortere RY, Kleven MS, Kolaczkowski M, Zimmer L. Translating biased agonists from molecules to medications: serotonin 5-HT(1A) receptor functional selectivity for CNS disorders. Pharmacol Ther. 2022;229:107937. https://doi.org/10.1016/j.pharmthera.2021.107937 .
doi: 10.1016/j.pharmthera.2021.107937
pubmed: 34174274
Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998;355(2–3):245–56. https://doi.org/10.1016/s0014-2999(98)00483-x .
doi: 10.1016/s0014-2999(98)00483-x
pubmed: 9760039
Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology. 2004;29(5):847–59. https://doi.org/10.1038/sj.npp.1300390 .
doi: 10.1038/sj.npp.1300390
pubmed: 14985704
Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(3):243–9. https://doi.org/10.4088/JCP.v64n0304 .
doi: 10.4088/JCP.v64n0304
pubmed: 12716264
Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008;69(4):571–7. https://doi.org/10.4088/jcp.v69n0408 .
doi: 10.4088/jcp.v69n0408
pubmed: 18373383
Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull. 1990;26(2):219–22.
pubmed: 1978372
Lapierre YD, Silverstone P, Reesal RT, Saxena B, Turner P, Bakish D, et al. A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. J Clin Psychopharmacol. 1998;18(4):268–73. https://doi.org/10.1097/00004714-199808000-00002 .
doi: 10.1097/00004714-199808000-00002
pubmed: 9690691
Stahl SM, Kaiser L, Roeschen J, Hesselink JMK, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol. 1998;1(1):11–8. https://doi.org/10.1017/s1461145798001059 .
doi: 10.1017/s1461145798001059
pubmed: 11281940
Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychopharmacol. 1990;10(3 Suppl):6S-12S.
doi: 10.1097/00004714-199006001-00003
pubmed: 1973941
Penttila J, Hirvonen J, Tuominen L, Lumme V, Ilonen T, Nagren K, et al. Verbal memory and 5-HT1A receptors in healthy volunteers–a PET study with [carbonyl-(11)C]WAY-100635. Eur Neuropsychopharmacol. 2016;26(3):570–7. https://doi.org/10.1016/j.euroneuro.2015.12.028 .
doi: 10.1016/j.euroneuro.2015.12.028
pubmed: 26775837
Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol. 2008;11(4):465–76. https://doi.org/10.1017/S1461145707008140 .
doi: 10.1017/S1461145707008140
pubmed: 17971260
Clifford EM, Gartside SE, Umbers V, Cowen PJ, Hajos M, Sharp T. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br J Pharmacol. 1998;124(1):206–12. https://doi.org/10.1038/sj.bjp.0701796 .
doi: 10.1038/sj.bjp.0701796
pubmed: 9630361
pmcid: 1565357
Newman-Tancredi A, Chaput C, Gavaudan S, Verriele L, Millan MJ. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology. 1998;18(5):395–8. https://doi.org/10.1016/S0893-133X(97)00169-3 .
doi: 10.1016/S0893-133X(97)00169-3
pubmed: 9536453
Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci. 1993;14(7):262. https://doi.org/10.1016/0165-6147(93)90125-4 .
doi: 10.1016/0165-6147(93)90125-4
pubmed: 8212321
Portella MJ, de Diego-Adelino J, Ballesteros J, Puigdemont D, Oller S, Santos B, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2011;72(7):962–9. https://doi.org/10.4088/JCP.09m05827blu .
doi: 10.4088/JCP.09m05827blu
pubmed: 21034693
Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2010;24(4):513–20. https://doi.org/10.1177/0269881108097714 .
doi: 10.1177/0269881108097714
pubmed: 18832428
Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, et al. beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 2000;23(3):285–93. https://doi.org/10.1016/S0893-133X(00)00109-3 .
doi: 10.1016/S0893-133X(00)00109-3
pubmed: 10942852
Newman-Tancredi A, Cussac D, Marini L, Millan MJ. Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol Pharmacol. 2002;62(3):590–601. https://doi.org/10.1124/mol.62.3.590 .
doi: 10.1124/mol.62.3.590
pubmed: 12181435
Newman-Tancredi A, Cussac D, Ormiere AM, Lestienne F, Varney MA, Martel JC. Bell-shaped agonist activation of 5-HT(1A) receptor-coupled Galphai(3) G-proteins: receptor density-dependent switch in receptor signaling. Cell Signal. 2019;63:109383. https://doi.org/10.1016/j.cellsig.2019.109383 .
doi: 10.1016/j.cellsig.2019.109383
pubmed: 31376526
Scorza MC, Llado-Pelfort L, Oller S, Cortes R, Puigdemont D, Portella MJ, et al. Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment. Br J Pharmacol. 2012;167(5):1021–34. https://doi.org/10.1111/j.1476-5381.2011.01770.x .
doi: 10.1111/j.1476-5381.2011.01770.x
pubmed: 22050051
pmcid: 3492984
Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. 2018;17(4):243–60. https://doi.org/10.1038/nrd.2017.229 .
doi: 10.1038/nrd.2017.229
pubmed: 29302067
pmcid: 5936084
Sniecikowska J, Newman-Tancredi A, Kolaczkowski M. From receptor selectivity to functional selectivity: the rise of biased agonism in 5-HT1A receptor drug discovery. Curr Top Med Chem. 2019;19(26):2393–420. https://doi.org/10.2174/1568026619666190911122040 .
doi: 10.2174/1568026619666190911122040
pubmed: 31544717
Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol. 2010;160(8):1929–40. https://doi.org/10.1111/j.1476-5381.2010.00738.x .
doi: 10.1111/j.1476-5381.2010.00738.x
pubmed: 20649591
pmcid: 2958639
Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P. In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. Psychopharmacology. 2012;221(2):261–72. https://doi.org/10.1007/s00213-011-2569-9 .
doi: 10.1007/s00213-011-2569-9
pubmed: 22147258
Assie MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortere R, Koek W, et al. F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol. 2010;13(10):1285–98. https://doi.org/10.1017/S1461145709991222 .
doi: 10.1017/S1461145709991222
pubmed: 20059805
Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, et al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Exp Neurol. 2015;271:335–50. https://doi.org/10.1016/j.expneurol.2015.05.021 .
doi: 10.1016/j.expneurol.2015.05.021
pubmed: 26037043
Depoortere R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney MA, et al. Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model. J Psychopharmacol. 2019;33(11):1456–66. https://doi.org/10.1177/0269881119860666 .
doi: 10.1177/0269881119860666
pubmed: 31290370
Depoortere R, Bardin L, Auclair AL, Bruins Slot LA, Newman-Tancredi A. Marble burying in NMRI male mice is preferentially sensitive to pre- versus postsynaptic 5-HT1A receptor biased agonists. Pharmacology. 2021;106(1–2):114–8. https://doi.org/10.1159/000509729 .
doi: 10.1159/000509729
pubmed: 32950991
Powell WH, Annett LE, Depoortere R, Newman-Tancredi A, Iravani MM. The selective 5-HT(1A) receptor agonist NLX-112 displays anxiolytic-like activity in mice. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(2):149–57. https://doi.org/10.1007/s00210-021-02183-2 .
doi: 10.1007/s00210-021-02183-2
pubmed: 34821958
Jastrzebska-Wiesek M, Partyka A, Rychtyk J, Sniecikowska J, Kolaczkowski M, Wesolowska A, et al. Activity of serotonin 5-HT(1A) receptor biased agonists in rat: anxiolytic and antidepressant-like properties. ACS Chem Neurosci. 2018;9(5):1040–50. https://doi.org/10.1021/acschemneuro.7b00443 .
doi: 10.1021/acschemneuro.7b00443
pubmed: 29266914
Ali M, Fahmy M, Haggag W, El-Tantawy A, Hassan H. Evaluation of cognitive impairment in patients with major depressive disorder in remission. Middle East Current Psychiatry-Mecpsych. 2021;28(1):71. https://doi.org/10.1186/s43045-021-00149-x .
doi: 10.1186/s43045-021-00149-x
Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust NZ J Psychiatry. 2009;43(12):1105–17. https://doi.org/10.3109/00048670903279887 .
doi: 10.3109/00048670903279887
Warburton EC, Harrison AA, Robbins TW, Everitt BJ. Contrasting effects of systemic and intracerebral infusions of the 5-HT1A receptor agonist 8-OH-DPAT on spatial short-term working memory in rats. Behav Brain Res. 1997;84(1–2):247–58. https://doi.org/10.1016/s0166-4328(96)00154-4 .
doi: 10.1016/s0166-4328(96)00154-4
pubmed: 9079789
Madjid N, Tottie EE, Luttgen M, Meister B, Sandin J, Kuzmin A, et al. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther. 2006;316(2):581–91. https://doi.org/10.1124/jpet.105.092262 .
doi: 10.1124/jpet.105.092262
pubmed: 16223872
Luttgen M, Elvander E, Madjid N, Ogren SO. Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat. Neuropharmacology. 2005;48(6):830–52. https://doi.org/10.1016/j.neuropharm.2005.01.007 .
doi: 10.1016/j.neuropharm.2005.01.007
pubmed: 15829255
Chamberlain SR, Muller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol. 2007;21(2):210–5. https://doi.org/10.1177/0269881107068066 .
doi: 10.1177/0269881107068066
pubmed: 17329302
Takahashi M, Iwamoto K, Kawamura Y, Nakamura Y, Ishihara R, Uchiyama Y, et al. The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol. 2010;25(3):260–7. https://doi.org/10.1002/hup.1105 .
doi: 10.1002/hup.1105
pubmed: 20373478
Depoortere R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol. 2010;20(9):641–54. https://doi.org/10.1016/j.euroneuro.2010.04.005 .
doi: 10.1016/j.euroneuro.2010.04.005
pubmed: 20488670
Depoortere RY, Auclair AL, Newman-Tancredi A. NLX-101, a cortical 5-HT(1A) receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition. Brain Res. 2021;1765:147493. https://doi.org/10.1016/j.brainres.2021.147493 .
doi: 10.1016/j.brainres.2021.147493
pubmed: 33887253
Paul J. Experimental medicine approaches in CNS drug development. In: Nomikos GG, Feltner DE, editors. Translational medicine in CNS drug development. Elsevier; 2019. p. 63–80.
doi: 10.1016/B978-0-12-803161-2.00005-9
McAllister-Williams RH, Massey AE. EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans. Psychopharmacology. 2003;166(3):284–93. https://doi.org/10.1007/s00213-002-1339-0 .
doi: 10.1007/s00213-002-1339-0
pubmed: 12589521
Cowen PJ, Power AC, Ware CJ, Anderson IM. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br J Psychiatry. 1994;164(3):372–9. https://doi.org/10.1192/bjp.164.3.372 .
doi: 10.1192/bjp.164.3.372
pubmed: 8199791
Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12(8):467–77. https://doi.org/10.1038/nrn3027 .
doi: 10.1038/nrn3027
pubmed: 21731066
Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161(7):1256–63. https://doi.org/10.1176/appi.ajp.161.7.1256 .
doi: 10.1176/appi.ajp.161.7.1256
pubmed: 15229059
Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409–18. https://doi.org/10.1016/S2215-0366(17)30015-9 .
doi: 10.1016/S2215-0366(17)30015-9
pubmed: 28153641
pmcid: 5410405
Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011;25(9):1159–67. https://doi.org/10.1177/0269881110376689 .
doi: 10.1177/0269881110376689
pubmed: 20660010
Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. J Psychopharmacol. 2011;25(9):1148–58. https://doi.org/10.1177/0269881110367722 .
doi: 10.1177/0269881110367722
pubmed: 20530590
Norbury R, Taylor MJ, Selvaraj S, Murphy SE, Harmer CJ, Cowen PJ. Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology. 2009;206(2):197–204. https://doi.org/10.1007/s00213-009-1597-1 .
doi: 10.1007/s00213-009-1597-1
pubmed: 19585106
Bernasconi F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX. The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. Eur Neuropsychopharmacol. 2015;25(4):474–82. https://doi.org/10.1016/j.euroneuro.2015.01.009 .
doi: 10.1016/j.euroneuro.2015.01.009
pubmed: 25637265
Fisher PM, Meltzer CC, Ziolko SK, Price JC, Moses-Kolko EL, Berga SL, et al. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat Neurosci. 2006;9(11):1362–3. https://doi.org/10.1038/nn1780 .
doi: 10.1038/nn1780
pubmed: 17013380
Selvaraj S, Mouchlianitis E, Faulkner P, Turkheimer F, Cowen PJ, Roiser JP, et al. Presynaptic serotoninergic regulation of emotional processing: a multimodal brain imaging study. Biol Psychiatry. 2015;78(8):563–71. https://doi.org/10.1016/j.biopsych.2014.04.011 .
doi: 10.1016/j.biopsych.2014.04.011
pubmed: 24882568
Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron. 2010;65(1):40–52. https://doi.org/10.1016/j.neuron.2009.12.003 .
doi: 10.1016/j.neuron.2009.12.003
pubmed: 20152112
pmcid: 2941196
Pizzagalli DA. Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation? Am J Psychiatry. 2022;179(7):458–69. https://doi.org/10.1176/appi.ajp.20220423 .
doi: 10.1176/appi.ajp.20220423
pubmed: 35775159
pmcid: 9308971
Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2015;30(3):152–63. https://doi.org/10.1002/hup.2475 .
doi: 10.1002/hup.2475
Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA Jr. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607. https://doi.org/10.1177/0269881114568041 .
doi: 10.1177/0269881114568041
pubmed: 25691504
pmcid: 5116382
McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67(5):439–45. https://doi.org/10.1016/j.biopsych.2009.11.001 .
doi: 10.1016/j.biopsych.2009.11.001
pubmed: 20034615
pmcid: 2828549
Walsh AEL, Huneke NTM, Brown R, Browning M, Cowen P, Harmer CJ. A dissociation of the acute effects of bupropion on positive emotional processing and reward processing in healthy volunteers. Front Psychiatry. 2018;9:482. https://doi.org/10.3389/fpsyt.2018.00482 .
doi: 10.3389/fpsyt.2018.00482
pubmed: 30386259
pmcid: 6198095
Admon R, Pizzagalli DA. Dysfunctional reward processing in depression. Curr Opin Psychol. 2015;4:114–8. https://doi.org/10.1016/j.copsyc.2014.12.011 .
doi: 10.1016/j.copsyc.2014.12.011
pubmed: 26258159
Langley C, Armand S, Luo Q, Savulich G, Segerberg T, Sondergaard A, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. 2023;48(4):664–70. https://doi.org/10.1038/s41386-022-01523-x .
doi: 10.1038/s41386-022-01523-x
pubmed: 36683090
pmcid: 9938113
Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21(5):461–71. https://doi.org/10.1177/0269881106069938 .
doi: 10.1177/0269881106069938
pubmed: 17050654
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211–7. https://doi.org/10.1192/bjp.bp.108.051110 .
doi: 10.1192/bjp.bp.108.051110
pubmed: 19721109
Assié M, Ravailhe V, Benas C, Newman-Tancredi A. Differential effects of 5-HT1A receptor agonists on extracellular levels of 5-HT in hippocampus and of dopamine in frontal cortex of freely moving rats. In: British Association for Psychopharmacology Summer Meeting. Harrogate, Poster ID. 2008.
Llado-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex. 2012;22(7):1487–97. https://doi.org/10.1093/cercor/bhr220 .
doi: 10.1093/cercor/bhr220
pubmed: 21893679
Cabanu S, Pilar-Cuellar F, Zubakina P, Florensa-Zanuy E, Senserrich J, Newman-Tancredi A, et al. Molecular signaling mechanisms for the antidepressant effects of NLX-101, a selective cortical 5-HT1A receptor biased agonist. Pharmaceuticals. 2022;15(3):337. https://doi.org/10.3390/ph15030337 .
doi: 10.3390/ph15030337
pubmed: 35337135
pmcid: 8954942
Colwell MJ, Tagomori H, Chapman S, Gillespie AL, Cowen PJ, Harmer CJ, Murphy SE. Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research. Transl Psychiatry. 2022;12(1):484. https://doi.org/10.1038/s41398-022-02249-6 .
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40. https://doi.org/10.1017/S0033291713002535 .
doi: 10.1017/S0033291713002535
pubmed: 24168753
CANTAB CC. CANTAB® [Cognitive assessment software]. 2019. https://cambridgecognition.com/ . Accessed 8 June 2023.
Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry. 2003;160(2):334–40. https://doi.org/10.1176/appi.ajp.160.2.334 .
doi: 10.1176/appi.ajp.160.2.334
pubmed: 12562581
Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–37. https://doi.org/10.1038/npp.2015.52 .
doi: 10.1038/npp.2015.52
pubmed: 25687662
pmcid: 4839526
D’Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015;40(1):36–40.
pubmed: 25628505
pmcid: 4296590
Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry. 2018;23(5):1127–33. https://doi.org/10.1038/mp.2017.104 .
doi: 10.1038/mp.2017.104
pubmed: 28533517
Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis. JAMA Psychiat. 2022;79(4):300–12. https://doi.org/10.1001/jamapsychiatry.2021.4313 .
doi: 10.1001/jamapsychiatry.2021.4313
Cole JC, Rodgers RJ. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology. 1994;114(2):288–96. https://doi.org/10.1007/BF02244851 .
doi: 10.1007/BF02244851
pubmed: 7838922
Koek W, Patoiseau J-F, Assié M-B, Cosi C, Kleven MS, Dupont-Passelaigue E, et al. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther. 1998;287(1):266–83.
pubmed: 9765347
Koek W, Vacher B, Cosi C, Assie MB, Patoiseau JF, Pauwels PJ, et al. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol. 2001;420(2–3):103–12. https://doi.org/10.1016/s0014-2999(01)01011-1 .
doi: 10.1016/s0014-2999(01)01011-1
pubmed: 11408031
Wieland S, Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology. 1990;101(4):497–504. https://doi.org/10.1007/BF02244228 .
doi: 10.1007/BF02244228
pubmed: 1975107
Chojnacka-Wojcik E, Tatarczynska E, Golembiowska K, Przegalinski E. Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology. 1991;30(7):711–7. https://doi.org/10.1016/0028-3908(91)90178-e .
doi: 10.1016/0028-3908(91)90178-e
pubmed: 1681449
Silva RC, Brandao ML. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav. 2000;65(2):209–16. https://doi.org/10.1016/s0091-3057(99)00193-8 .
doi: 10.1016/s0091-3057(99)00193-8
pubmed: 10672971
Brown PC. Application number: 022567, NDA: 22-567, in tertiary pharmacology/toxicology review (PHARMACOLOGY REVIEW). 2010. CENTER FOR DRUG EVALUATION AND RESEARCH.
Griebel G, Rodgers RJ, Perrault G, Sanger DJ. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav. 1997;57(4):817–27. https://doi.org/10.1016/s0091-3057(96)00402-9 .
doi: 10.1016/s0091-3057(96)00402-9
pubmed: 9259011
Kasahara K, Hashimoto S, Hattori T, Kawasaki K, Tsujita R, Nakazono O, et al. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. J Pharmacol Sci. 2015;127(1):109–16. https://doi.org/10.1016/j.jphs.2014.11.008 .
doi: 10.1016/j.jphs.2014.11.008
pubmed: 25704026
Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Reperant C, Orvoen S, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147–59. https://doi.org/10.1016/j.neuropharm.2013.05.014 .
doi: 10.1016/j.neuropharm.2013.05.014
pubmed: 23721744
Sanchez C, Westrich L, Zhong H, Nielsen S, Boyle N, Hentzer M, et al. P. 2. B. 008 In vitro effects of the multimodal antidepressant Lu AA21004 at human and rat 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors, and 5-HT transporters. Eur Neuropsychopharmacol. 2012;22:S245–6.
doi: 10.1016/S0924-977X(12)70366-8
Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–21. https://doi.org/10.1021/jm101459g .
doi: 10.1021/jm101459g
pubmed: 21486038
Cao BJ, Rodgers RJ. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. I. Pindolol enantiomers and pindobind 5-HT1A. Pharmacol Biochem Behav. 1997;58(2):583–91. https://doi.org/10.1016/s0091-3057(97)00280-3 .
doi: 10.1016/s0091-3057(97)00280-3
pubmed: 9300623
Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, et al. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol. 2009;156(2):338–53. https://doi.org/10.1111/j.1476-5381.2008.00001.x .
doi: 10.1111/j.1476-5381.2008.00001.x
pubmed: 19154445
pmcid: 2697830
Cao BJ, Rodgers RJ. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216–525 and NAN-190. Pharmacol Biochem Behav. 1997;58(2):593–603. https://doi.org/10.1016/s0091-3057(97)00279-7 .
doi: 10.1016/s0091-3057(97)00279-7
pubmed: 9300624